A framework for achieving compromise between industry and civil society.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Caulfield, T.A. & Gold, E.R. FORUM for Appl. Res. & Pub. Pol. 75 (Spring 2000).
Gold, E.R. Nat. Biotechnol. 18, 1217–1218 (2000).
Barboza, D. Monsanto faces growing skepticism on two fronts. New York Times , August 5 (1999), p. C1.
Brown, P. & Vidal, J. GM investors told to sell their shares. The Guardian, August 25 (1999).
Whitney, C.R. Europe loses its appetite for high-tech food. New York Times, June 27 (1999), p. D3.
Gaskell, G. et al. Nat. Biotechnol. 18, 935–938 (2000).
Priest, S.H. Nat. Biotechnol. 18, 939–942 (2000).
Canadian Biotechnology Secretariat, Public opinion research into biotechnology issues. (Canadian Biotechnology Secretariat, Ottawa, ON; 2000).
Taylor, C. The malaise of modernity. (Ananci, Concord, ON, Canada; 1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gold, E. Moving the gene patent debate forward. Nat Biotechnol 18, 1319–1320 (2000). https://doi.org/10.1038/82460
Issue Date:
DOI: https://doi.org/10.1038/82460
This article is cited by
-
DNA patents and diagnostics: not a pretty picture
Nature Biotechnology (2010)
-
Biotechnology patents: strategies for meeting economic and ethical concerns
Nature Genetics (2002)